PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 3 47-3, 2003, Pages

  Ye, Ji Ming ^a   Iglesias, Miguel A ^a   Watson, David G ^a   Ellis, Bronwyn ^a   Wood, Leonie ^a   Jensen, Per Bo ^b   Sørensen, Rikke Veggerby ^b   Larsen, Philip Just ^b   Cooney, Gregory J ^a   Wassermann, Karsten ^c   Kraegen, Edward W ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Rheoscience   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Adipokines; Insulin resistance; Peroxisome proliferator activated receptor subtypes; Tissue lipids

Indexed keywords

ADIPONECTIN; INSULIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; RAGAGLITAZAR; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; GLUCOSE; OXAZINE DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FAT INTAKE; FATTY LIVER; HEPATOMEGALY; HORMONE ACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; COMPARATIVE STUDY; DRUG POTENTIATION; GLUCOSE CLAMP TECHNIQUE; LIVER; METABOLISM; PATHOPHYSIOLOGY; SKELETAL MUSCLE; WISTAR RAT;

ANIMALS; DIETARY FATS; FATTY LIVER; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MUSCLE, SKELETAL; OXAZINES; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0037362638     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00299.2002     Document Type: Article

References (49)

1. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, and O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100: 3149-3153, 1997.
2. Antinozzi PA, Segall L, Prentki M, McGarry JD, and Newgard CB. Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion. A re-evaluation of the long-chain acyl-CoA hypothesis. J Biol Chem 273: 16146-16154, 1998.
3. Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Kawasaki S, Okamura A, and Sekihara H. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone. Diabetes 48: 1579-1585, 1999.
4. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, and Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 48: 94-98, 1999.
5. Berg AH, Combs TP, Du X, Brownlee M, and Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953, 2001.
6. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, and Moller DE. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 274: 6718-6725, 1999.
7. Bligh EG and Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
8. Carey DG, Jenkins AB, Campbell LV, Freund J, and Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45: 633-638, 1996.
9. Chan TM and Exton JH. A rapid method for the determination of glycogen content and radioactivity in small quantities. Anal Biochem 71: 96-105, 1976.
10. Chaput E, Saladin R, Silvestre M, and Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271: 445-450, 2000.
11. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, and Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007, 2002.
12. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, and Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98: 1004-1009, 1996.
13. Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr., Ogilvie KM, Liu S, and Kauffman RF. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 51: 1083-1087, 2002.
14. Fonseca V, Rosenstock J, Patwardhan R, and Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283: 1695-1702, 2000.
15. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, and Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010, 2001.
16. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, and Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642, 2000.
17. Hansen PA, Han DH, Nolte LA, Chen M, and Holloszy JO. DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol Regul Integr Comp Physiol 273: R1704-R1708, 1997.
18. Hegarty BD, Cooney GJ, Kraegen EW, and Furler SM. Increased efficiency of fatty acid uptake contributes to lipid accumulation in skeletal muscle of high fat-fed insulin-resistant rats. Diabetes 51: 1477-1484, 2002.
19. Holden PR and Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 22: 1-8, 1999.
20. Jensen J, Serup P, Karlsen C, Nielsen TF, and Madsen OD. mRNA profiling of rat islet tumors reveals nkx 6.1 as a beta-cell-specific homeodomain transcription factor. J Biol Chem 271: 18749-18758, 1996.
21. Kahn CR, Chen L, and Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106: 1305-1307, 2000.
22. Kersten S, Desvergne B, and Wahli W. Roles of PPARs in health and disease. Nature 405: 421-424, 2000.
23. Kim JY, Nolte LA, Hansen PA, Han DH, Kawanaka K, and Holloszy JO. Insulin resistance of muscle glucose transport in male and female rats fed a high-sucrose diet. Am J Physiol Regul Integr Comp Physiol 276: R665-R672, 1999.
24. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 341: 498-511, 1999.
25. Kraegen EW, James DE, Jenkins AB, and Chisholm DJ. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol Endocrinol Metab 248: E353-E362, 1985.
26. Kraegen EW, James DE, Storlien LH, Burleigh KM, and Chisholm DJ. In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: assessment by euglycaemic clamp plus deoxyglucose administration. Diabetologia 29: 192-198, 1986.
27. Larsen PJ, Jensen PB, Larsen LK, Vrang N, Sørensen RV, and Wassermann K. Ragaglitazar prevents intraabdominal fat accumulation and is devoid of orexigenic and adipogenic effects in diet-induced obese rats. Diabetes 51, Suppl 2: 565-P, 2002.
28. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, and Zhou G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 276: 31521-31527, 2001.
29. Maegawa H, Obata T, Shibata T, Fujita T, Ugi S, Morino K, Nishio Y, Kojima H, Hidaka H, Haneda M, Yasuda H, Kikkawa R, and Kashiwagi A. A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Diabetologia 42: 151-159, 1999.
30. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, and Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844-1850, 2001.
31. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, and Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339-343, 2002.
32. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
33. Moya-Camarena SY, Van den Heuvel JP, and Belury MA. Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta 1436: 331-342, 1999.
34. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, and Kadowaki T. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47: 1841-1847, 1998.
35. Murase T, Kondo H, Hase T, Tokimitsu I, and Saito M. Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates. Biochim Biophys Acta 1530: 15-22, 2001.
36. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, and Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43: 1203-1210, 1994.
37. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, and Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272: 27307-27312, 1997.
38. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Woldike HF, Fleckner J, Andersen AS, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, and Wulff EM. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem 45: 789-804, 2002.
39. Silverman JF, Pories WJ, and Caro JF. Liver pathology in diabetes mellitus and morbid obesity, pathological, and biochemical considerations. Pathol Annu 24: 275-302, 1989.
40. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998.
41. Storlien LH, James DE, Burleigh KM, Chisholm DJ, and Kraegen EW. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol Endocrinol Metab 251: E576-E583, 1986.
42. Tontonoz P, Hu E, Devine J, Beale EG, and Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15: 351-357, 1995.
43. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, and Semenkovich CF. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107: 1025-1034, 2001.
44. Wahl HG, Kausch C, Machicao F, Rett K, Stumvoll M, and Haring HU. Troglitazone downregulates delta-6 desaturase gene expression in human skeletal muscle cell cultures. Diabetes 51: 1060-1065, 2002.
45. Wang JL, Chinookoswong N, Scully S, Qi M, and Shi ZQ. Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology 140: 2117-2124, 1999.
46. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, and Kliewer SA. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142: 1269-1277, 2001.
47. Wolfrum C, Borrmann CM, Borchers T, and Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA 98: 2323-2328, 2001.
48. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, and Kadowaki T. The mechanisms by which both heterozygous PPAR-gamma deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276: 41245-41254, 2001.
49. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, and Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50: 411-417, 2001.